Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus

Mohammed Salah Eldin Abdelbaky¹, Tarek Ahmad El Mamoun², Fatma Ibrahim Mabrouk¹ and Rasha Mohamad Hassan¹*

Abstract

Background: Hydroxychloroquine (HCQ) is an antimalarial drug, recently used in COVID-19 treatment. Also it is considered over many years the cornerstone in treating systemic lupus erythematosus (SLE) in adults and children. The incidence of retinal affection and retinal toxicity from hydroxychloroquine is rare, but even after the HCQ is stopped, loss of vision may not be reversible and may continue to progress. Fundus autofluorescence (FAF) is one of the screening methods recommended by AAO used for the diagnosis of hydroxychloroquine retinopathy. Our aim is to detect early HCQ-induced retinopathy among SLE patients and the risk factors for its development by using fundus autofluorescence.

Results: In the present study, 11.3% of the studied patients had significant visual field changes upon testing. Of those, 6.3% had abnormal fundus autofluorescence. We found a significant statistical relation between hydroxychloroquine retinopathy and the duration and cumulative dose of hydroxychloroquine therapy (p value = 0.003) and decreased best-corrected visual acuity of both eyes (p value = 0.000). There was no relationship between HCQ retinopathy detected by fundus autofluorescence and daily dose of HCQ/kg, age, sex, and SLEDAI score.

Conclusion: Frequency of SLE patients who had confirmed HCQ-induced retinopathy was 6.3%. Hydroxychloroquine could be safely used in all SLE patients regardless of age, sex, and SLE activity. Routine ophthalmological assessment is recommended for SLE patients who received HCQ especially for those who received HCQ longer than 7 years. Fundus autofluorescence is a modern objective tool which is specific for the early detection of HCQ retinopathy.

Keywords: SLE, Hydroxychloroquine retinopathy, Frequency, Risk factors, Fundus autofluorescent

Background

HCQ is used in treating SLE in adults and children. It is effective for the treatment of the specific skin lesions of cutaneous LE (CLE) [1], whether acute, subacute, or chronic. It is very effective for the amelioration of joint and constitutional symptoms and for the prevention of clinical relapse [30].

The incidence of retinal toxicity induced from hydroxychloroquine is rare, but even if the HCQ is stopped, loss of vision may not be reversible [18, 20] and may continue to be more advanced [16]. It is important that patients and doctors are aware of and observe this drug ocular side effect. And before starting treatment with hydroxychloroquine, a complete ophthalmic assessment should be done to detect any baseline maculopathy [30].

Patients are usually asymptomatic, and their visual acuity is preserved at the early stages. Actually, objective changes precede a patient’s complaint of vision loss. Rarely, when the investigation was done, the patient may...
be found to have minimal changes in night vision, diminished color vision, or a paracentral scotoma [14]. Paracentral scotoma which is experienced by the patient can worsen, and the patient often has a subjective complaint of reading difficulty that occurs before any changes are found on dilated fundus examination [15].

Two years ago, Royal College of Ophthalmologists (RCOphth) recommended that all patients received hydroxychloroquine for greater than 5 years should undergo 10-2 Humphrey visual field testing (using a white stimulus), followed by pupillary dilation and imaging with both spectral domain optical coherence tomography (SD-OCT) and/or wide field fundus autofluorescent (FAF) [35].

Fundus autofluorescence (FAF) is one of the objective screening methods for HCQ retinopathy [9]. A parafoveal increased autofluorescence signal is detected in the early stages of disease, with mottled decrease in parafoveal autofluorescence as Retinal Pigment Epithelium (RPE) degeneration becomes established in later stages of disease [9].

**Aim of the study**

This study was designed to get frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus using fundus autofluorescence.

**Methods**

The current study included 80 systemic lupus erythematosus patients who were diagnosed according to Systemic Lupus International Collaborating Clinics (SLICC) classification criteria [24]. They were recruited from the outpatient rheumatology clinic and inpatients at the Department of Internal Medicine, Rheumatology Division. All patients have no visual symptoms; also, other causes of retinopathy (DM, HTN, drug induced as tamoxifen) were excluded from the study. The study was approved by the local research ethical committee. All participants gave written consent after explaining the nature of the study.

The study is a cross-sectional observational study. All patients were subjected to the following:

- **Clinical assessment:** Full medical history was taken from each patient, including information about duration and dosage of HCQ intake. Rheumatological examination as well as assessment of disease activity using systemic lupus erythematosus disease activity index (SLED A1) were done [2].

- **Laboratory assessment** is as follows: CBC, ESR, CRP, serum complement level (C3 and C4) by radial immunodiffusion assay, complete urine analysis, urinary protein creatinine ratio, anti-nuclear antibody (ANA) by immunofluorescent test, anti-dsDNA by ELISA, serum creatinine, blood urea nitrogen (BUN), and fasting blood glucose.

- **Ophthalmological assessment** is as follows: fundus examination by an experienced ophthalmologist, best-corrected visual acuity by Landolt chart on 6 m and expressed in decimal, and the 10-2 Humphrey visual field analyzer. Visual field images of 80 patients were collected. Scotoma point locations were also recorded; abnormality was defined as partial or full ring scotoma mainly affecting the parafoveal region [6].

- **Fundus autofluorescence** is as follows: it was done by an experienced ophthalmologist who was blinded to the clinical and laboratory data, by using a scanning laser ophthalmoscopy VX-20 retinal camera (KOWA, JAPAN). The intensity of the FAF image depends on the concentration and amount of lipofuscin and to a lesser extent, other fluorophores. Lesions can be classified as hyper-autofluorescent, results from alterations in lipofuscin metabolism, and its accumulation in RPE cells; hypoautofluorescent arises from decreased amount of lipofuscin or PRE atrophy [9, 34].

In HCQ-induced retinopathy, FAF images show early hyper-autofluorescent parafoveal ring corresponding to photoreceptor damage, which decreases in signal strength over time due to RPE atrophy (hypoautofluorescent). Advanced stages of the disease include bilateral bull’s-eye maculopathy. The area of hypoautofluorescent may spread to involve the central fovea and even the entire fundus [9] (Figs. 1, 2, and 3).

As regards the finding of the fundus autofluorescent, the patients will be divided into 2 groups: group 1, patients who have normal FAF; and group 2, who have abnormal FAF.

**Statistical analysis**

The data were collected, tabulated, and statistically analyzed. Analysis of data was done by a personal computer using SPSS (Statistical Program for Social Science) under Windows version 17 as follows: description of quantitative variables as mean, standard deviation (SD), and range; description of qualitative variables as number (no) and percentage. Chi-square test was used to compare qualitative variables. Unpaired t test was used to compare two independent groups as regards quantitative variables. Spearman’s correlation co-efficient rank test was used to rank different variables against each other positively or inversely ($p < 0.05$ = insignificant, $p \leq 0.05$ = significant, $p \leq 0.001$ = highly significant).

Receiver operating characteristic curve (ROC) was used to assess the best cutoff point with its sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under curve (AUC).
Fig. 1 Normal fundus autoflourscent

Fig. 2 Retinal Pigmented Epithelium by fundus autoflourscent (RPE)
Ethical consideration
Approval of study conduction was obtained from the Ethical Review Committee at the Faculty of Medicine, the purpose of this study was explained to all participants, confidentiality was assured, and written consent was obtained from all participants.

Results
Eighty SLE patients on hydroxychloroquine therapy were included. The clinical data are shown in Table 1. Ninety percent of studied patients were females and 10% were males; their mean ages were 31.24 ± 7.41 range from 18 to 50 years. Their mean daily HCQ dose/kg was 4.89 ± 1.01 ranges from 2.2 to 7.1 mg/kg.

The HCQ therapy duration ranges from 0.3 to 15 years. According to the SLEDAI score, 15% of the studied patients are in remission, 27.5% are having mild disease activity, 28.8% are having moderate activity, 22.5% are having high activity, and 6.2% are having very high activity. Visual field tests were done for all patients taking HCQ. Significant changes in visual field tests were found in nine patients (11.3%). FAF confirmed hydroxychloroquine retinopathy in (6.3%) of those patients.

Comparison between patients who have normal FAF (group 1) and those who have abnormal FAF (group 2), there were statistically significant differences between patients who have normal FAF (group 1) and those who have abnormal FAF (group 2) as regards the duration of hydroxychloroquine therapy \((p = 0.003)\), cumulative dose of HCQ therapy \((p = 0.000)\), and decreased the best-corrected visual acuity of both eyes \((p = 0.000)\) (Table 2).

The mean weight-based daily dose of HCQ in group 1 was 4.86 ± 1.01, and in group 2 was 5.28 ± 0.88. There was no significant statistical difference between both groups regarding the daily dose of hydroxychloroquine therapy.

The mean age in group 1 was 31.15 ± 7.22, and in group 2 was 32.60 ± 10.85. There was no significant statistical difference between both groups regarding age. Regarding the SLEDAI score, it was ranged from 0 to 25 in group 1 and ranged from 5 to 20 in group 2. There was no statistically significant difference between both groups regarding SLEDAI score.

The sensitivity and specificity of FAF (the ability of FAF to detect the true positive and true negative HCQ retinopathy cases) in relation to the visual field test was 59% and 100% with accuracy of 94% (Tables 3 and 4). Predictors for abnormal FAF cases (by using calculating the receiver operating characteristic curves) were the duration of hydroxychloroquine therapy longer than 7 years and best-corrected visual acuity (BCVA) of both eyes ≤ 0.5 (Figs. 4, 5 and Table 5).

The previous table shows that FAF can predict visual field results with a sensitivity of 55.6%, specificity of 100.0%, and accuracy of 94.81.
### Table 1 Clinical data of SLE patients at the time of enrollment

| Clinical parameter         | N (%) | Mean (Range)       |
|----------------------------|-------|--------------------|
| Age (Y)                    | 31.24±7.41 | 18–50             |
| Sex (F/M)                  | 72 (90%)/8 (10%) |
| Hcq therapy                |       |                   |
| Duration of HCQ therapy (years) |       | 0.3–15             |
| Daily dose mg/kg           | 4.89±1.01 | 2.2–7.1           |
| Cumulative dose (g)        | 713.67±498.75 | 36.5±2190         |
| SLEDAI                     | 0–25   |                   |
| BCVA                       | 0.85±0.30 | 0.1–1/0.16–1    |
| ANA positive (IU/ml)       | 75 (93.8%)          |
| Ant-DNA positive (U/ml)    | 49 (61.3%)          |
| Fundus                     |        |                   |
| Normal                     | 77 (96.2%)         |
| Bull’s eye                 | 3 (3.8%)           |
| Fundus autofluorescent     |        |                   |
| Normal                     | 75 (93.8%)          |
| Abnormal (bull’s eye/RPE)  | 5 (6.3%)           |
| Visual field               |        |                   |
| Normal                     | 68 (85.0%)          |
| Significant change         | 9 (11.3%)           |
| Non-reliable               | 3 (33.8%)           |

**SLEDAI** Systemic Lupus Erythematosus Disease Activity Index, **HCQ** hydroxychloroquine, **BCVA** best-corrected visual acuity, **ESR** erythrocyte sedimentation rate, **FAF** fundus autofluorescence, **ANA** antinuclear antibody, **Anti-DNA** anti-deoxyribonucleic acid, **RPE** retinal pigmented epithelium

### Table 2 Comparison between normal FAF group and abnormal FAF group

|                  | Normal FAF | Abnormal FAF | Test value | P value | Sig.   |
|------------------|------------|--------------|------------|---------|--------|
|                  | No. = 75   | No. = 5      |            |         |        |
| Age (Y)          | 31.15±7.22 | 32.60±10.85  | 0.423      | 0.674   | NS     |
| Sex (F/M)        | 68/7 (90/9%) | 4/1 (80/20%) | 0.593      | 0.441   | NS     |
| Duration of HCQ therapy (years) | 5 (2–6) | 10 (8–10) | –3.017c | 0.003 | HS     |
| Daily dose (mg/kg) | 4.86±1.01 | 5.28±0.88 | –0.896a | 0.373 | NS     |
| Cumulative dose (g) | 661.96±461.26 | 1489.20±418.08 | –3.901 | 0.000 | HS     |
| Fundus           | Normal     | 75 (100%)    | 2 (40.0%)  | 46.753a | 0.000 | HS     |
|                 | RPE        | 0 (0%)       | 3 (60.0%)  |         |        |
| BCVA RT          | Mean±SD    | 0.88±0.27    | 0.40±0.37  | 3.702b  | 0.000 | HS     |
|                 | Range      | 0.10–1.1     | 0.1–1.0    |         |        |
| BCVA LT          | Mean±SD    | 0.93±0.19    | 0.31±0.17  | 6.873c  | 0.000 | HS     |
|                 | Range      | 0.16–1.0     | 0.16–0.5   |         |        |

**P** value > 0.05: non-significant (NS); **P** value < 0.05: significant (S); **P** value < 0.01: highly significant (HS)

*SLEDAI* Systemic Lupus Erythematosus Disease Activity Index, **HCQ** hydroxychloroquine, **BCVA** best-corrected visual acuity, **FAF** fundus autofluorescence, **RPE** retinal pigmented epithelium

*Chi-square test

Independent *t* test

*Mann-Whitney test*
Discussion

Over the last decade, clinicians have emphasized the role of hydroxychloroquine in SLE treatment [8, 27]. Not only its efficacy in preventing SLE flares and damage, but it has an important role against the development of diabetes mellitus, thrombotic events, and dyslipidemia in patients with SLE. This results in improving the survival in SLE patients [4].

A well-known complication in long-term HCQ intake and high cumulative dose therapy is the development of a HCQ-related maculopathy, carrying the possibility of occurrence of irreversible sight-threatening bull’s-eye maculopathy (BEM). The primary site of toxicity in HCQ retinopathy is the photoreceptor layer with secondary degeneration of the retinal pigmented epithelium (RPE) [26].

This study was designed to get frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematos.

It included 72 females (90%) and 8 males (10%), whose ages ranged from 18 to 50 years with mean age of 31.24 years. The higher frequency of SLE among women has resulted from the estrogen hormonal effect [5]. SLE can occur at any age; it is most common in childbearing age although it has been reported in both extremes of life [10].

In the current study, the frequency of confirmed hydroxychloroquine retinopathy by using 10–12 Humphrey visual field and FAF was 6.3%. This was higher than Tangtavorn et al. [29] and Cabral et al. [3] who found the prevalence of toxic retinopathy caused by antimalarial drugs were 3.2% and 4.15%, respectively. However, it is less than Palma Sanchez et al. [25] who demonstrated in a retrospective study an overall rate of retinal toxicity (13.5%). The previous studies used another method (SD-OCT and electoretinogram (ERG) plus 10–12 visual field testing) for detection of hydroxychloroquine retinopathy in different rheumatological diseases (SLE and RA).

Using the visual field testing showed significant changes in another 4 patients who were considered as having possible hydroxychloroquine retinopathy by the Royal College of Ophthalmology (RCOphth) definition of the hydroxychloroquine retinopathy [35]. This proved the high sensitivity of the 10–12 Humphrey visual field test. Melles and Marmor [17] reported that visual field testing is considered the most sensitive tool for detecting the earliest stages of retinopathy, although its results are subjective and affected variably by patient responses.

Between the studied risk factors, the hydroxychloroquine retinopathy depends mainly on the duration of hydroxychloroquine therapy. This is in agreement with a number of studies related to the risk of retinopathy to increase duration of HCQ treatment (Palma Sanchez et al. [25]; Wolfe and Marmor [31]). Also, Petri et al. [23] found that there was a 1% risk of retinopathy in the first 5 years of HCQ treatment, 1.8% from 6 to 10 years, and 3.3% from 11 to 15 years, so the risk increases after 16 years of use, even after 20 years.

It is known that hydroxychloroquine takes about 1 month and needs about 6 months to achieve full elimination from the body. Hydroxychloroquine toxicity is caused by the accumulation of the drug in the outer retinal layer leading to macular edema and or bilateral granular depigmentation of the RPE in the macula with continued exposure to the drug. This can progress to an atrophic bull’s eye with concentric rings of hypopigmentation and hyperpigmentation surrounding the fovea. These changes can progress to include other areas of the fundus causing widespread atrophy [19, 32].

Moreover, the Royal College of Ophthalmologists (RCOphth) 2009 guidelines preferred ophthalmological screening for patients who have received HCQ therapy for more than 5 years. This became evidence since 2011.

Also, we found that the cumulative dose of the hydroxychloroquine therapy was significantly related to the hydroxychloroquine retinopathy that was in agreement with Petri et al. [23] and Lenfant et al. [11]. Previously, the cumulative dose was described as one of the risk factors of the hydroxychloroquine retinopathy [14, 17]. In 2016, Marmor et al. reported that the patients using a recommended dose had significant risk after decades of

### Table 3: Comparison between the 10–12 visual field and FAF

| Normality       | Normal Visual field | Abnormal Visual field |
|-----------------|---------------------|-----------------------|
|                 | No. | %     | No. | %       | Test value | P value | Sig. |
| Normal          | 68  | 100.0%| 4   | 44.4%   | 40.401     | < 0.001 | H5  |
| Abnormal        | 0   | 0.0% | 5   | 55.6%   |            |         |     |

### Table 4: Diagnostic accuracy of FAF in prediction of visual field results

| Variables | Accuracy | Sensitivity | Specificity | +PV | −PV |
|-----------|----------|-------------|-------------|-----|-----|
| FAF       | 94.81%   | 55.6%       | 100.0%      | 100.0% | 94.4% |
use. But this risk is mainly dependent on the duration of use relative to the daily dose based on body weight.

In this study, weight-based daily dose was not a risk factor for HCQ retinopathy. However, the previous studies emphasized that the daily dose of more than 5 mg/kg is one of the most important risk factors for HCQ retinopathy \[7, 11, 17\]. The explanation might be that most of the studied patients’ weights were above 70 kg and most of them received 400 mg/day or less, also the low socioeconomic level of our patients might make them non-compliant to the treatment.

In 2011, American Academy of Ophthalmology (AAO) guidelines (screening for HCQ retinopathy) advised weight-based HCQ dosing of 6.5 mg/kg/day with a maximum dose of 400 mg/day (exceptions were obese and short stature patients, dosage based on ideal body weight was used). Finally, the latest 2016 AAO guidelines and 2018 RCOphth guidelines returned to use ABW and recommended < 5.0 mg/kg of ABW \[35\].

Regarding age and sex, there was no significant relation between hydroxychloroquine retinopathy and the age and sex of examined patients. This agrees with similar results found by Yaylali et al. \[33\] and Levy et al. \[12\] while Petri et al. \[23\] and Ding et al. \[7\] found that increased age above 60 years is considered a risk factor for HCQ retinopathy. We did not find these results as most of our patients are females (90%) and their ages ranged from 18 to 50 years.

Also, we found no significant relation between hydroxychloroquine retinopathy and SLE activity by SLEDAI score and the immunological markers. This was consistent with the recent study done by Lenfant et al. \[11\]. HCQ is a very important drug for SLE treatment; up till now, it cannot be proved that the disease activity has a role in the pathogenesis of HCQ retinopathy.

By comparing the routine fundus examination and fundus autofluorescence, the latter was better for detecting early hydroxychloroquine retinopathy. This was

Table 5 Receiver operating characteristic curve (ROC) for predictors of abnormal FAF cases

| Variables                  | Cutoff point | AUC   | Sensitivity | Specificity | +PV  | −PV  |
|----------------------------|--------------|-------|-------------|-------------|------|------|
| Duration of therapy (years)| > 7          | 0.900 | 100.00      | 82.67       | 27.8 | 100.0|
| BCVA RT                    | ≤ 0.5        | 0.832 | 80.00       | 85.33       | 26.7 | 98.5 |
| BCVA LT                    | ≤ 0.5        | 0.963 | 100.00      | 89.33       | 38.5 | 100.0|

BCVA best-corrected visual acuity, AUC area under curve, +PV true positive value, −PV false positive value
already reported in many previous studies [22, 28]. They reported that patients on HCQ therapy and had no clinical retinopathy, fundus autofluorescence is helpful to early detect and monitor for retinal affection in patients taking HCQ.

FAF was found as a specific method but not sensitive for early detection of the Hcq retinopathy in relation to the visual field testing (the sensitivity 59%, the specificity 100%). This is in agreement with Marmor [15] and Pandya et al. [21] who reported that FAF is not recommended as a primary screening tool. Instead, it is recommended by the AAO guidelines that FAF must be used with other imaging tools [13].

In this study, the duration of HCQ therapy of more than 7 years was a predictor for HCQ retinopathy among our patients by using the fundus autofluorescence. This is in agreement with Wolfe and Marmor [31] and Mavrikakis et al. [16] in a prospective cohort study to assess retinal toxicity among patients who received the recommended dose. They had no retinal toxicity during a follow-up period of 6 years. In 2016, the American Academy of Ophthalmology recommended screening for those who received HCQ more than 7 years. Fundus autofluorescence is a modern objective tool which is specific for early detection of HCQ retinopathy.

Limitations of our study should be pointed out. One of the limitations of our study is that like most others, it was a cross-sectional study. Another limitation is that all of the included patients come from a low-socioeconomic level that may affect compliance, follow-up, and SLE treatment strategy. In addition, spectral domain optical coherence tomography and multifocal electroretinogram (mFERG) were not available for full assessment for the presence of any retinopathy related to HCQ treatment.

Abbreviations
AAO: American Academy of Ophthalmology; ABW: Actual body weight; BCVA: Best-corrected visual acuity; DM : Diabetes mellitus; HCQ: Hydroxychloroquine; HTN : Hypertension; ROphth: Royal College of Ophthalmologists; SD-OCT: Spectral domain optical coherence tomography; SLE: Systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics

Acknowledgements
To all the main authors.

Authors’ contributions
MA gave the idea of the research and design of the work. TM was responsible for revision the ophthalmological assessment in the current research. FM and RH contributed to writing and shared in the clinical part of
the research at Ain Shams University Hospital (from the rheumatology department and the rheumatology clinic). RH contributed to writing (main role). The authors read and approved the final manuscript.

Funding
The present work was not funded.

Availability of data and materials
The data that support the finding of this study are available from Rasha Mohamad Hassan (corresponding author).

Declarations

Ethics approval and consent to participate
Approval of study conduction was obtained from the Research Ethics Committee at the Faculty of Medicine Ain Shams University, the purpose of this study was explained to all participants, confidentiality was assured, and written consent was obtained from all participants. Ethical committee number FWA00017585

Confidentiality of data
Date of acceptance 9th February 2021.

Consent for publication
Written consent was obtained from all participants to publish the finding of this study.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Medicine Division of Rheumatology, Ain Shams University, Cairo, Egypt. 2Department of Ophthalmology, Ain Shams University, Cairo, Egypt.

Received: 29 January 2021 Accepted: 26 April 2021
Published online: 08 June 2021

References
1. Alarcón GS, McGwin G, Bertolli AM et al (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66(9):1168–1172
2. Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLED AI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630-640
3. Cabral RTS, Klumb EM, Couto MIN et al (2019) Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography. Arq Bras Oftalmol 82(1):12–17
4. Coades-Chalumeau N, Galicier L, Aumaître O et al (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 72(11):1786–1792
5. Costenbader KH, Feskanich D, Stampfer MJ et al (2007) Reproductive and menstrual factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56(4):1251–1262
6. Cukras C, Huyhn N, Vitale S et al (2015) Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmol 122:356–366
7. Ding HJ, Dunniston AK, Rao VK et al (2015) Hydroxychloroquine-related retinal toxicity. Rheumatol 55(6):957–967
8. Fessler BJ, Alarcon GS, McGwin G et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:145–180
9. Kellner U, Renner AB, Tillack H (2006) Fundus autofluorescence and mFERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47:3531–3538
10. Lam GK, Petri M (2005) Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 23:5120–5132
11. Lentfer T, Salah S, Leroux G et al (2020) Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatol 59(12):3807–3816
12. Levy GD, Munz SJ, Paschal J et al (1997) Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 40:1482–1486
13. Marmor M, Mieler W, Kellner U et al (2016) Recommendations on Screening for Chloroquine and Hydroxychloroquine for retinopathy. Am Acad Ophthalmol 123:1386–1394
14. Marmor MF, Kellner U, Lai TY et al (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmol 118:415–422
15. Marmor MF (2013) Fundus autofluorescence is not the best early screen for hydroxychloroquine toxicity. JAMA Ophthalmol 131:1487–1488
16. Mavrikakis I, Sfikas PP, Mavrikakis E et al (2003) The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmol 110:1321–1326
17. Melles R, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460
18. Michaelides M (2011) Retinal toxicity associated with hydroxychloroquine and chloroquine. Arch Ophthalmol 129(1):30
19. Mittel A, Wong BJ, Brenner M et al (2013) Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 131:1187–1197
20. Moschos MM, Nitoda E, Chatzidiak IP et al (2015) Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electrotoretinography study. Drug Des Devel Ther 9:2993–2999
21. Pandya HK, Robinson M, Mandal N et al (2015) Hydroxychloroquine retinopathy: a review of imaging. Indian J Ophthalmol 63(7):570
22. Park SP, Siringo FS, Pensec N et al (2013) Comparison of fundus autofluorescence between fundus camera and confocal scanning laser ophthalmoscope–based systems. Ophthalmic Surg Lasers Imaging Retina 44(6):536–543
23. Petri M, Ehalfat M, Li J, Magder LS et al (2020) Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol 73(3):448–453
24. Petri M, Orbai AM, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686
25. Palma Sanchez D, Velazquez ER, Marin SS et al (2013) Toxicidad retiniana por antipaludicos: frecuencia y factores de riesgo. Reumatol Clin. 9:259–262
26. Reichel C, Berlin A, Radun V et al (2020) Quantitative fundus autofluorescence in systemic chloroquine/hydroxychloroquine therapy. Trans Vis Sci Tech 9(4):2
27. Shinjo SK, Bonfa E, Wojdyła D et al (2010) Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL). Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62(3):855–862
28. Solberg Y, Dyss C, Möller B et al (2019) Fluorescence lifetimes in patients with hydroxychloroquine retinopathy. Invest Ophthalmol Visual Sci 60(6):2165
29. Tangtavorn N, Yospaiboon Y, Ratapanakorn T et al (2016) Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologic patients. Clin Ophthalmol 10:2179–2185
30. Wallace DJ (2014): Antimalarial drugs in the treatment of rheumatic disease. In: Furst DE, Romain PL (eds). UpToDate. Waltham (MA): UpToDate; [Updated 2014 Dec 1; Cited 2014 Dec 20]. Available from www.uptodate.com.
31. Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 62(6):775–784
32. Yarn JC, Kwock AK (2006) Occular toxicity of hydroxychloroquine. Hong Kong Med J 12(4):294
33. Yavali SA, Ekinci A, Sadigov F et al (2013) Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort. Int Ophthalmol 33:627–634
34. Yung M, Klufas MA, Sarraf D et al (2016) Clinical applications of fundus autofluorescence in retinal disease. Int J Retina Vitr 2:121–125
35. Yusuf IH, Foot B, Galloway G et al (2018) Royal College of Ophthalmologists Guideline Development Group - Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye 32:1168–1173

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.